脾多肽注射液在非小细胞肺癌术后辅助化疗中的临床应用观察  

Usage of Lienal Polypeptide Injection combined with post-operative chemotheray in patients with non-small cell lung cancer

作　　者：宋伟安[1] 查鹏[1] 李学昌[1] 刘军强[1] 文锋[1] 李军[1] 岳彩迎[1] 王伟[1] 

机构地区：[1]海军总医院胸外科,北京100048

出　　处：《北京医学》2015年第2期188-190,共3页Beijing Medical Journal

摘　　要：目的探讨非小细胞肺癌患者在术后辅助化疗中应用脾多肽注射液的临床效果。方法 127例术后需行辅助化疗的非小细胞肺癌患者随机为观察组(65例)和对照组(62例)。观察组在辅助化疗同时加用脾多肽注射液,对照组仅给予辅助化疗。观察2组患者治疗后的全身状况、毒副反应并进行外周血T细胞亚群分析。结果辅助化疗后,观察组患者的平均KPS评分明显高于对照组(87.2±6.4 vs.74.2±5.9,P<0.05),且观察组T细胞亚群分析各项免疫指标也显著优于对照组(P<0.05);观察组化疗相关血液毒性发生率低于对照组(P<0.05)。结论在非小细胞肺癌患者术后辅助化疗过程中,应用脾多肽注射液能有效改善患者的全身状况和免疫功能。Objective To investigate the clinical effects of Lienal Polypeptide Injection combined with post-oper-ative chemotherapy in patients with non-small cell lung cancer after surgical therapy. Methods One hundred and twen-ty-seven post-operative patients with non-small cell lung cancer were randomly divided into investigative group （n=65） and control group （n=62）. Patients in the investigative group were administrated with Lienal Polypeptide Injections when undergoing post-operative adjective chemotherapy, while patients in the control group were given only adjective chemotherapy. Results After chemotherapy, the average KPS value in patients of the investigative group was higher than that in the control group （87.2±6.4 vs.74.2±5.9, P＆lt;0.05）. At the same time, the rate of chemotherapy related hematologic toxicity in the investigative group was significantly lower than that in the control group （P〈 0.05）. Conclusion During post-operative chemotherapy, the addition of Lienal Polypeptide Injection will improve the general condition and the im-mune ability of patients with non-small cell lung cancer.

关 键 词：非小细胞肺癌 辅助化疗 脾多肽注射液 KPS评分 免疫功能 毒副反应 

分 类 号：R734.2[医药卫生—肿瘤]